Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Refocus Group, a medical device company engaged in the research and development of treatments for eye disorders, has received approval from the FDA to begin the final round of clinical trial surgeries for its Scleral Spacing Procedure for the surgical treatment of presbyopia, or close-up vision loss.
Subscribe to our email newsletter
The FDA approval to expand to the final phase of the clinical trial was based on Refocus Group’s submission of preliminary data from phase II surgeries through mid-July 2005.
“We are now advancing toward the final stages of the clinical trial process of our surgical treatment for presbyopia,” said Terry Walts, president and CEO of Refocus Group. “We remain pleased with our clinical results to date, which continue to support our belief in the Scleral Spacing Procedure as a no-compromise mainstay surgical solution for the reduction or elimination of the need for reading glasses for close-up vision for many people after age 40.”